Advertisement

Protease and Protease Inhibitors in Familial Amyloidotic Polyneuropathy

  • Noriaki Adachi
  • Shin’ichi Shoji
  • Shin’ichi Nakagawa
  • Chang-Sung Koh
  • Naoyuki Tsukada
  • Nobuo Yanagisawa
Chapter

Abstract

The concentration of six protease inhibitors were studied in patients with familial amyloidotic polyneuropathy (FAP) and in healthy controls, and no significant differences were detected. The proteolytic effect of brinase, an enzyme of Aspergillus oryza, on amyloid tissue sections from patients with FAP was also evaluated. Amyloid fibrils were degraded by brinase, while the tissue structures remained fairly intact.

Keywords

Protease Inhibitor Amyloid Fibril Aspergillus Oryzae Secondary Amyloidosis Familial Amyloidotic Polyneuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adachi N., S Shoji, S Nakagawa, C-S Koh, N Tsukada, N Yanagisawa(1987) Studies of protease and protease inhibitors in familial amyloidotic polyneuropathy. J Neurol Sci. 81: 79–84CrossRefGoogle Scholar
  2. Adachi N., S Shoji, N Yanagisawa (in press) Bleeding manifestations in 24 patients with familial amyloidotic polyneuropathy. Europ NeurolGoogle Scholar
  3. Costa, P.P., A.S. Figueira and F.R. Bravo (1987) Amyloid fibril protein related to prealbumin in familial amyloid polyneuropathy. Proc. Natl. Acad. Sci. USA, 75:4499–4503CrossRefGoogle Scholar
  4. Eriksson, S. (1960) Determination of serum trypsin inhibitor capacity. Acta Med. Scand., 432(suppl.):6–85Google Scholar
  5. Kato H, N Adachi, S Iwanaga, K Abe, K Takada, T Kimura, S Sakakibara (1980) A fluorogenic substrate method for the estimation of kallikrein in urine. J Biochem. 87:1127–1132Google Scholar
  6. Kato H, N Adachi, Y Ohno, S Iwanaga, K Takada and S Sakakibara (1980) New fluorogenic peptide substrates for plasmin. J Biochem 88:183–190Google Scholar
  7. Kedar I., M. Ravid and E. Sohar (1974) Demonstration of amyloid degrading activity in normal human serum. Proc. Soc. Exp. Biol. Med., 145: 343–345Google Scholar
  8. Kedar I, Sohar E, Ravid M. (1982) Degradation of amyloid by a serum component and inhibition of degradation. J Lab Clin Med 99:693–700Google Scholar
  9. Saraiva, M.J.M., P.P. Costa and D.S. Goodman (1986) Genetic expression of a transthyretin mutation in typical and late-onset Portugese families with familial amyloidotic polyneuropathy. Neurology, 36: 1423–1417Google Scholar
  10. Skogen B. and E. Amundsen (1982) Degradation of amyloid proteins with protease I from Aspergillus oryzae. In vivo increase in SAA clearance rate after enzyme infusion. Scand. J. Immunol., 14:389–396CrossRefGoogle Scholar
  11. Wegelius O., A.M. Teppo and C.P.J. Maury (1982) Reduced amyloid A-degrading activity in serum in amylo-dosis associated with rheumatoid arthritis Br. Med. J., 284: 617–619CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Noriaki Adachi
    • 1
  • Shin’ichi Shoji
    • 1
  • Shin’ichi Nakagawa
    • 1
  • Chang-Sung Koh
    • 1
  • Naoyuki Tsukada
    • 1
  • Nobuo Yanagisawa
    • 1
  1. 1.Department of Medicine (Neurology)Shinshu University School of MedicineMatsumoto 390Japan

Personalised recommendations